Veronique de Jager

548 total citations
20 papers, 182 citations indexed

About

Veronique de Jager is a scholar working on Infectious Diseases, Epidemiology and Molecular Biology. According to data from OpenAlex, Veronique de Jager has authored 20 papers receiving a total of 182 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Infectious Diseases, 9 papers in Epidemiology and 6 papers in Molecular Biology. Recurrent topics in Veronique de Jager's work include Tuberculosis Research and Epidemiology (17 papers), Antibiotics Pharmacokinetics and Efficacy (6 papers) and Mycobacterium research and diagnosis (5 papers). Veronique de Jager is often cited by papers focused on Tuberculosis Research and Epidemiology (17 papers), Antibiotics Pharmacokinetics and Efficacy (6 papers) and Mycobacterium research and diagnosis (5 papers). Veronique de Jager collaborates with scholars based in United States, South Africa and Netherlands. Veronique de Jager's co-authors include Andreas H. Diacon, Kim Narunsky, Rodney Dawson, Elin M. Svensson, Naadira Vanker, Rob E. Aarnoutse, Stephen H. Gillespie, Patrick Phillips, Norbert Heinrich and Anthony J. Garcia‐Prats and has published in prestigious journals such as Nature Medicine, American Journal of Respiratory and Critical Care Medicine and Antimicrobial Agents and Chemotherapy.

In The Last Decade

Veronique de Jager

18 papers receiving 180 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Veronique de Jager United States 8 134 78 40 37 34 20 182
Caryn M. Upton South Africa 9 127 0.9× 80 1.0× 33 0.8× 26 0.7× 24 0.7× 24 213
Minje Han South Korea 12 102 0.8× 91 1.2× 26 0.7× 62 1.7× 57 1.7× 27 320
Samiksha Ghimire Netherlands 9 160 1.2× 90 1.2× 36 0.9× 38 1.0× 122 3.6× 19 263
Patricia Pecora Fulco United States 10 180 1.3× 75 1.0× 27 0.7× 31 0.8× 21 0.6× 27 275
Vycke Yunivita Indonesia 8 154 1.1× 99 1.3× 123 3.1× 30 0.8× 40 1.2× 34 269
Modulakgotla Sebe South Africa 5 133 1.0× 97 1.2× 31 0.8× 39 1.1× 10 0.3× 6 164
Jana Winckler South Africa 8 166 1.2× 97 1.2× 42 1.1× 19 0.5× 73 2.1× 21 225
Lali Mikiashvili Georgia 7 152 1.1× 93 1.2× 38 0.9× 29 0.8× 48 1.4× 16 174
Wael A. Alghamdi Saudi Arabia 12 186 1.4× 131 1.7× 44 1.1× 61 1.6× 118 3.5× 26 337
Arianna D. Pranger Netherlands 7 146 1.1× 118 1.5× 38 0.9× 58 1.6× 111 3.3× 9 294

Countries citing papers authored by Veronique de Jager

Since Specialization
Citations

This map shows the geographic impact of Veronique de Jager's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Veronique de Jager with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Veronique de Jager more than expected).

Fields of papers citing papers by Veronique de Jager

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Veronique de Jager. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Veronique de Jager. The network helps show where Veronique de Jager may publish in the future.

Co-authorship network of co-authors of Veronique de Jager

This figure shows the co-authorship network connecting the top 25 collaborators of Veronique de Jager. A scholar is included among the top collaborators of Veronique de Jager based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Veronique de Jager. Veronique de Jager is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Heinrich, Norbert, Veronique de Jager, Patrick Phillips, et al.. (2025). Population pharmacokinetics and exposure–response relationship of the antituberculosis drug BTZ-043. Journal of Antimicrobial Chemotherapy. 80(5). 1315–1323. 1 indexed citations
2.
Janssen, Saskia, Caryn M. Upton, Veronique de Jager, et al.. (2025). Telacebec, a Potent Agent in the Fight against Tuberculosis: Findings from a Randomized, Phase 2 Clinical Trial and Beyond. American Journal of Respiratory and Critical Care Medicine. 211(8). 1504–1512. 3 indexed citations
3.
4.
Diacon, Andreas H., Clifton E. Barry, Ray Y. Chen, et al.. (2024). A first-in-class leucyl-tRNA synthetase inhibitor, ganfeborole, for rifampicin-susceptible tuberculosis: a phase 2a open-label, randomized trial. Nature Medicine. 30(3). 896–904. 20 indexed citations
5.
Jager, Veronique de, Patrizio Giacomini, Janet A. Fairley, et al.. (2024). 112P Reporting of molecular test results from cell-free DNA analyses: Expert consensus recommendations from the 2023 European Liquid Biopsy Society ctDNA workshop. Annals of Oncology. 35. S259–S259.
6.
Ignatius, Elisa H., Veronique de Jager, Caryn M. Upton, et al.. (2024). High-Dose Isoniazid Lacks EARLY Bactericidal Activity against Isoniazid-resistant Tuberculosis Mediated by katG Mutations: A Randomized Phase II Clinical Trial. American Journal of Respiratory and Critical Care Medicine. 210(3). 343–351. 6 indexed citations
7.
Zou, Yuanxi, Veronique de Jager, Anneke C. Hesseling, et al.. (2023). Relative bioavailability of delamanid 50 mg tablets dispersed in water in healthy adult volunteers. British Journal of Clinical Pharmacology. 91(4). 957–967. 3 indexed citations
8.
Jager, Veronique de, Rodney Dawson, Andreas H. Diacon, et al.. (2023). Drug interaction potential of high-dose rifampicin in patients with pulmonary tuberculosis. Antimicrobial Agents and Chemotherapy. 67(10). e0068323–e0068323. 6 indexed citations
9.
Jager, Veronique de, et al.. (2023). 95P Automatic data processing to identify EGFR mutations in pathology reports of patients with non-small cell lung cancer (NSCLC). ESMO Open. 8(1). 101905–101905. 1 indexed citations
10.
11.
Kontsevaya, Irina, Jan Heyckendorf, Doris Hillemann, et al.. (2023). Transrenal Mycobacterium tuberculosis DNA in pulmonary tuberculosis patients during the first 14 days of treatment. Microbiology Spectrum. 11(6). e0234823–e0234823. 1 indexed citations
12.
Chirehwa, Maxwell, Elisa H. Ignatius, Richard Court, et al.. (2022). Pharmacokinetics of standard versus high-dose isoniazid for treatment of multidrug-resistant tuberculosis. Journal of Antimicrobial Chemotherapy. 77(9). 2489–2499. 7 indexed citations
13.
Jager, Veronique de, Nikhil Gupte, Sílvia Nunes, et al.. (2022). Early Bactericidal Activity of Meropenem plus Clavulanate (with or without Rifampin) for Tuberculosis: The COMRADE Randomized, Phase 2A Clinical Trial. American Journal of Respiratory and Critical Care Medicine. 205(10). 1228–1235. 23 indexed citations
14.
Jager, Veronique de, Elana van Brakel, Helmuth Reuter, et al.. (2021). The Population Pharmacokinetics of Meropenem in Adult Patients With Rifampicin-Sensitive Pulmonary Tuberculosis. Frontiers in Pharmacology. 12. 637618–637618. 3 indexed citations
15.
Brake, Lindsey H. M. te, Veronique de Jager, Kim Narunsky, et al.. (2021). Increased bactericidal activity but dose-limiting intolerability at 50 mg·kg−1rifampicin. European Respiratory Journal. 58(1). 2000955–2000955. 36 indexed citations
16.
Brake, Lindsey te, Veronique de Jager, Kim Narunsky, et al.. (2020). Increased Bactericidal Activity But Dose-Limiting Tolerability at 50 mg/kg Rifampicin. SSRN Electronic Journal.
17.
Diacon, Andreas H., Sachiko Miyahara, Rodney Dawson, et al.. (2020). Assessing whether isoniazid is essential during the first 14 days of tuberculosis therapy: a phase 2a, open-label, randomised controlled trial. The Lancet Microbe. 1(2). e84–e92. 7 indexed citations
18.
Diacon, Andreas H., Veronique de Jager, Rodney Dawson, et al.. (2020). Fourteen-Day Bactericidal Activity, Safety, and Pharmacokinetics of Linezolid in Adults with Drug-Sensitive Pulmonary Tuberculosis. Antimicrobial Agents and Chemotherapy. 64(4). 23 indexed citations
19.
Svensson, Elin M., Jeannine du Bois, Veronique de Jager, et al.. (2018). Relative bioavailability of bedaquiline tablets suspended in water: Implications for dosing in children. British Journal of Clinical Pharmacology. 84(10). 2384–2392. 24 indexed citations
20.
Jager, Veronique de, Lize van der Merwe, Amour Venter, Peter R. Donald, & Andreas H. Diacon. (2017). Time Trends in Sputum Mycobacterial Load and Two-Day Bactericidal Activity of Isoniazid-Containing Antituberculosis Therapies. Antimicrobial Agents and Chemotherapy. 61(4). 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Caryn M. Upton Breakdown of academic impact, for papers by Minje Han Breakdown of academic impact, for papers by Samiksha Ghimire Breakdown of academic impact, for papers by Patricia Pecora Fulco Breakdown of academic impact, for papers by Vycke Yunivita Breakdown of academic impact, for papers by Modulakgotla Sebe Breakdown of academic impact, for papers by Jana Winckler Breakdown of academic impact, for papers by Lali Mikiashvili Breakdown of academic impact, for papers by Wael A. Alghamdi Breakdown of academic impact, for papers by Arianna D. Pranger
Rankless by CCL
2026